Raymond James Financial Inc. Purchases Shares of 501,734 Henry Schein, Inc. (NASDAQ:HSIC)

Raymond James Financial Inc. acquired a new stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 501,734 shares of the company's stock, valued at approximately $34,720,000. Raymond James Financial Inc. owned about 0.40% of Henry Schein at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bank of Nova Scotia boosted its stake in Henry Schein by 0.5% during the fourth quarter. Bank of Nova Scotia now owns 286,710 shares of the company's stock worth $19,840,000 after buying an additional 1,407 shares during the period. Invesco Ltd. lifted its holdings in shares of Henry Schein by 0.4% in the 4th quarter. Invesco Ltd. now owns 4,963,409 shares of the company's stock worth $343,468,000 after acquiring an additional 17,552 shares during the last quarter. FMR LLC lifted its holdings in shares of Henry Schein by 6.6% in the 4th quarter. FMR LLC now owns 3,498,033 shares of the company's stock worth $242,064,000 after acquiring an additional 217,143 shares during the last quarter. Lyrical Asset Management LP bought a new position in Henry Schein during the 4th quarter valued at about $126,655,000. Finally, Clarkston Capital Partners LLC lifted its stake in Henry Schein by 24.8% in the fourth quarter. Clarkston Capital Partners LLC now owns 1,744,225 shares of the company's stock worth $120,700,000 after purchasing an additional 346,420 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company's stock.

Henry Schein Stock Up 2.3 %

Shares of NASDAQ HSIC traded up $1.46 during midday trading on Tuesday, reaching $64.54. 772,480 shares of the company's stock traded hands, compared to its average volume of 1,613,759. The company has a market cap of $7.91 billion, a price-to-earnings ratio of 26.56, a P/E/G ratio of 2.13 and a beta of 0.84. Henry Schein, Inc. has a one year low of $60.56 and a one year high of $82.49. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The stock's 50 day simple moving average is $69.87 and its 200-day simple moving average is $71.88.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.23 by ($0.04). The company had revenue of $3.19 billion during the quarter, compared to analysts' expectations of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The company's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.66 earnings per share. On average, analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Philip A. Laskawy sold 2,604 shares of Henry Schein stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the transaction, the director now owns 24,805 shares of the company's stock, valued at $1,762,147.20. The trade was a 9.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the sale, the chief executive officer now directly owns 62,688 shares of the company's stock, valued at $4,460,251.20. The trade was a 6.05 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on HSIC shares. StockNews.com cut Henry Schein from a "buy" rating to a "hold" rating in a research note on Thursday, April 17th. Barrington Research reiterated an "outperform" rating and set a $90.00 target price on shares of Henry Schein in a research report on Wednesday, February 26th. Bank of America upgraded shares of Henry Schein from an "underperform" rating to a "buy" rating and upped their price target for the stock from $69.00 to $84.00 in a report on Monday, January 6th. UBS Group decreased their price objective on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a report on Wednesday, February 26th. Finally, Jefferies Financial Group upped their target price on shares of Henry Schein from $77.00 to $80.00 and gave the stock a "hold" rating in a research note on Thursday, January 23rd. Six investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $81.10.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.